NCT04666272 2026-02-19
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
Novartis
Active not recruiting
Clinical Trials
11 trialsNCT07419932 2026-02-19
NeoLATC
Fujian Medical University
Recruiting
NCT06262919 2025-12-30
Special Drug Use-results Surveillance of Tafinlar/Mekinist
Novartis
Recruiting
NCT04961619 2025-12-12
LEAD Melanoma
Novartis
Completed
NCT07092670 2025-09-05
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
Intergruppo Melanoma Italiano
Recruiting
NCT03944356 2025-03-12
Combi-EU
EuMelaReg gGmbH
Completed
NCT06532149 2024-08-09
EROS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT05988697 2023-10-12
Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Not yet recruiting
NCT04547946 2023-05-30
Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)
Novartis
Completed
NCT05171374 2022-06-01
RATIONALE
MelanomaPRO, Russia
Unknown
NCT02439411 2019-12-02
DEIS
Grupo Español Multidisciplinar de Melanoma
Completed